All Stories

  1. Phage Therapy for Bone and Joint Infections: Towards Clinical Translation
  2. Identification and Functional Insights into New Phage Tail-Like Bacteriocins (PTLBs) Targeting Pseudomonas aeruginosa as new antimicrobials
  3. An accurate amplification-free CRISPR/Cas12a-based assay for GES β-lactamase detection
  4. Studies in vitro and in vivo of phage therapy medical products (PTMPs) Targeting Clinical Strains of Klebsiella pneumoniae belonging to the clone ST512
  5. The world of phage tail-like bacteriocins: State of the art and biotechnological perspectives
  6. The LAMP-CRISPR-Cas13a technique for detecting the CBASS mechanism of phage resistance in bacteria
  7. Study of the probability of resistance to phage infection in a collection of clinical isolates of P s eudomonas aeruginosa in relation to the presence of Pf phages
  8. «The LAMP-CRISPR-Cas13a technique for detecting CBASS-mechanism of phage resistance in bacteria»
  9. «Studiesin vitroein vivoof Phage Therapy Medical Products (PTMPs) targeting clinical strains ofKlebsiella pneumoniaebelonging to the clone ST512»
  10. Mitomycin C as an Anti-Persister Strategy against Klebsiella pneumoniae: Toxicity and Synergy Studies
  11. Mitomycin C as an Anti-persister Strategy Against Klebsiella Pneumoniae: Toxicity and Synergy Studies
  12. Resistance against two lytic phage variants attenuates virulence and antibiotic resistance in Pseudomonas aeruginosa
  13. Improving phage therapy by evasion of phage resistance mechanisms
  14. Use of Galleria mellonella as an Animal Model for Studying the Antimicrobial Activity of Bacteriophages with Potential Use in Phage Therapy
  15. «Control of the phage defense mechanism by Quorum Sensing (QS) in clinical isolates ofKlebsiella pneumoniae»
  16. Molecular studies of phages-Klebsiella pneumoniae in mucoid environment: innovative use of mucolytic agents prior to the administration of lytic phages
  17. Prophage identification and molecular analysis in the genomes of Pseudomonas aeruginosa strains isolated from critical care patients
  18. CRISPR-Cas13a-Based Assay for Accurate Detection of OXA-48 and GES Carbapenemases
  19. Molecular Studies of Phages-Klebsiella pneumoniaein a Mucoid Environment: Innovative use of mucolytic agents prior to the administration of lytic phages
  20. Proteomic Study of the Interactions between Phages and the Bacterial Host Klebsiella pneumoniae
  21. Study of 32 new phage tail-like bacteriocins (pyocins) from a clinical collection of Pseudomonas aeruginosa and of their potential use as typing markers and antimicrobial agents
  22. Reverse Transcription-Loop-Mediated Isothermal Amplification-CRISPR-Cas13a Technology as a Promising Diagnostic Tool for SARS-CoV-2
  23. «Study of 32 new phage tail-like bacteriocins (pyocins) from a clinical collection of Pseudomonas aeruginosa and of their potential use as typing markers and antimicrobial agents»
  24. Molecular characteristics of phages located in Carbapenemase-Producing Escherichia coli clinical isolates: New Phage-Like Plasmids
  25. RT-LAMP-CRISPR-Cas13a technology as a promising diagnostic tool for the SARS-CoV-2 virus
  26. The role of PemIK (PemK/PemI) type II TA system from Klebsiella pneumoniae clinical strains in lytic phage infection
  27. Development of an Anti-Acinetobacter baumannii Biofilm Phage Cocktail: Genomic Adaptation to the Host
  28. Adaptation of clinical isolates of Klebsiella pneumoniae to the combination of niclosamide with the efflux pump inhibitor phenyl-arginine-β-naphthylamide (PaβN): co-resistance to antimicrobials
  29. Genomic Analysis of Molecular Bacterial Mechanisms of Resistance to Phage Infection
  30. Phenotypic and Genomic Comparison of Klebsiella pneumoniae Lytic Phages: vB_KpnM-VAC66 and vB_KpnM-VAC13
  31. Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of Klebsiella pneumoniae
  32. Genomic Analysis of Molecular Bacterial Mechanisms of Resistance to Phage Infection
  33. «PemIK (PemK/PemI) type II TA system from Klebsiella pneumoniae clinical strains inhibits lytic phage»
  34. Blue light directly modulates the quorum network in the human pathogen Acinetobacter baumannii
  35. CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
  36. CRISPR-Cas. A Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
  37. Blue Light Directly Modulates the Quorum Network in the Human Pathogen Acinetobacter baumannii
  38. Analysis of Complete Genome Sequence of Acinetobacter baumannii Strain ATCC 19606 Reveals Novel Mobile Genetic Elements and Novel Prophage
  39. Viral Related Tools against SARS-CoV-2
  40. Temperate Bacteriophages (Prophages) in Pseudomonas aeruginosa Isolates Belonging to the International Cystic Fibrosis Clone (CC274)
  41. Mechanisms of Tolerance and Resistance to Chlorhexidine in Clinical Strains of Klebsiella pneumoniae Producers of Carbapenemase: Role of New Type II Toxin-Antitoxin System, PemIK
  42. (p)ppGpp and Its Role in Bacterial Persistence: New Challenges
  43. Whole Transcriptomic Analysis of Mechanisms of Tolerance and Resistance to Chlorhexidine in Clinical Strains of Klebsiella Pneumoniae Producers of Carbapenemase
  44. Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae
  45. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens
  46. Strategies to Combat Multidrug-Resistant and Persistent Infectious Diseases
  47. Strategies to Combat Persistent Infectious Diseases
  48. Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii
  49. Combined Use of the Ab105-2фΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multiresistant Acinetobacter Baumannii
  50. Quorum and Light Signals Modulate Acetoin/Butanediol Catabolism in Acinetobacter spp.
  51. Multiplex Real-Time PCR-shortTUB Assay for Detection of the Mycobacterium tuberculosis Complex in Smear-Negative Clinical Samples with Low Mycobacterial Loads
  52. In vitro and in vivo efficacy of the combination of colistin and endolysins against clinical strains of Multi-Drug Resistant (MDR) pathogens
  53. Relationship Between Quorum Sensing and Secretion Systems
  54. Relationship Between the Quorum Network (Sensing/Quenching) and Clinical Features of Pneumonia and Bacteraemia Caused by A. baumannii
  55. Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments
  56. ighting antimicrobial resistance in ESKAPE pathogens
  57. Relationship between Tolerance and Persistence Mechanisms in Acinetobacter baumannii Strains with AbkAB Toxin-Antitoxin System
  58. Evolution of the Quorum network and the mobilome (plasmids and bacteriophages) in clinical strains of Acinetobacter baumannii during a decade
  59. Clostridium difficile Infection: Pathogenesis, Diagnosis and Treatment
  60. Response to Bile Salts in Clinical Strains of Acinetobacter baumannii Lacking the AdeABC Efflux Pump: Virulence Associated with Quorum Sensing
  61. Quorum sensing network in clinical strains of A. baumannii: AidA is a new quorum quenching enzyme
  62. Genome Sequence of AirborneAcinetobactersp. Strain 5-2Ac02 in the Hospital Environment, Close to the Species ofAcinetobacter towneri
  63. Genomic Evolution of Two Acinetobacter baumannii Clinical Strains from ST-2 Clones Isolated in 2000 and 2010 (ST-2_clon_2000 and ST-2_clon_2010)
  64. Genome Sequence of a Clinical Strain of Acinetobacter baumannii Belonging to the ST79/PFGE-HUI-1 Clone Lacking the AdeABC (Resistance-Nodulation-Cell Division-Type) Efflux Pump
  65. Toxin-Antitoxin Systems in Clinical Pathogens
  66. Recent Patents on Microbial Proteases for the Dairy Industry
  67. Cloning and Characterization of the Beer Foaming Gene CFG1from Saccharomyces pastorianus
  68. Texture classification using a new version of local binary patterns
  69. FPG1, a gene involved in foam formation in Saccharomyces cerevisiae
  70. Hydrolases as markers of wine aging